argenx SE ADR ARGX 深 沪
等待开盘 09-17 09:30:00 美东时间
752.32
-4.510
-0.60%
华盛通- 最 高759.79
- 今 开753.90
- 成交量 31.77万股
- 最 低 746.05
- 昨 收 756.83
- 总市值 460.42亿
- 52周最高 779.03
- 市盈率 静 58.97
- 换手率 0.52%
- 52周最低 510.055
- 委 比 -34.32%
- 总股本 6119.99万
- 历史最高 779.03
- 量 比 0.89
- 振 幅 1.82%
- 历史最低 19.00
- 每 手 1
- 风险率 51.97%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅432.99%！维持"投机性买入"评级，Unicycive Therapeutics获机构升目标价至21美元
今日重点评级关注：Benchmark：维持Unicycive Therapeutics"投机性买入"评级，目标价从3美元升至21美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从17美元升至25美元
09-16 09:48
Truist Securities Maintains Buy on argenx, Raises Price Target to $918
Truist Securities analyst Joon Lee maintains argenx (NASDAQ:ARGX) with a Buy and raises the price target from $700 to $918.
09-15 21:08
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today
argenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 12.84...
09-11 06:00
Is argenx Gaining or Losing Market Support?
argenx's (NYSE:ARGX) short percent of float has fallen 4.11% since its last rep...
09-09 03:00
B of A Securities Maintains Buy on argenx, Raises Price Target to $887
B of A Securities analyst Tazeen Ahmad maintains argenx (NASDAQ:ARGX) with a Buy and raises the price target from $880 to $887.
09-02 23:38
argenx to Present at Upcoming Investor Conferences
argenx, a global immunology company focused on severe autoimmune diseases, announced that its management team will participate in two investor conferences in September. On September 4, 2025, there will be a fireside chat at the Wells Fargo Healthcare Conference in Boston, MA. Another fireside chat will occur on September 8, 2025, at the Morgan Stanley Global Healthcare Conference in New York, NY. Webcasts of these presentations will be available ...
08-28 05:00
Assessing argenx: Insights From 11 Financial Analysts
In the latest quarter, 11 analysts provided ratings for argenx (NASDAQ:ARGX), s...
08-26 03:01
Argenx Targets FDA Label Expansion After Vyvgart Trial Success
Argenx reported positive Phase 3 Vyvgart data in seronegative myasthenia gravis, with plans for an FDA filing to expand the drug's label in 2025
08-25 20:41
argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG
argenx announced positive results from the ADAPT SERON study of VYVGART for AChR-Ab seronegative generalized myasthenia gravis (gMG). The study met its primary endpoint (p=0.0068) and showed clinically meaningful improvements in disease activity across all three subtypes: MuSK+, LRP4+, and triple seronegative. argenx plans to submit an sBLA to the FDA by end of 2025 to expand VYVGART's label. The study also demonstrated consistent safety and tole...
08-25 05:00
